Medical views and public opinions on cannabis (marijuana) have come a long way in the last several decades. Today, medicinal and recreational use of the plant and its derivatives are quickly gaining both acceptance and popularity.
What does this mean for people with diabetes who may use the plant or its constituents (where it is medically or recreationally legal)?
This article summarizes the major effects of cannabis and the derived compounds on physiology and various health conditions, particularly as they may relate to people with diabetes. However, cannabis and many of the associated products remain illegal at the federal level. Anything written in this article is for informational purposes only and is not intended to serve as medical advice.
Marijuana Laws in the United States
According to The National Organization for the Reform of Marijuana Laws (NORML), thirteen states have decriminalized marijuana use, a whopping thirty-two states have enacted medical marijuana laws, and ten states have fully legalized recreational marijuana use for adults.
Image credit: NORML
Medicinal Uses of Cannabis
It is well-established that there are numerous medicinal properties of cannabis. Reports of medicinal cannabis use date back thousands of years, and more and more studies are being conducted today, with increased tolerance, legal status at the local level, and more widely-accepted view of the potential health benefits.
How does it work? Briefly, our bodies have what is referred to as an endocannabinoid system—that is, the specific cellular receptors that can interact with several different compounds that are found in marijuana and can affect a variety of physiological processes. As can be seen in the diagrams below, these receptors are present in a variety of organs and tissues in humans.
Cannabis contains many different compounds. The two major active compounds are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Researchers note that “available research indicates that the main two compounds, d-9-THC and CBD, whilst having similar effects in certain domains, also have almost opposite effects to one another in other aspects.” This highlights why specific preparations (e.g., CBD only) may be especially useful for treating a particular health condition.
Which health conditions may benefit from the use of cannabis or its derivatives? Since the endocannabinoid system can affect numerous processes, there are many conditions that can be targeted.
- Autoimmune Diseases (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease)
- Cardiovascular Disease
- Liver Disease
- Neurodegenerative Diseases (e.g., Parkinson’s, Alzheimer;’s, Huntington’s)
- Psychiatric Disorders
So, marijuana can affect a variety of organs and exerts both physical and psychological effects.
Many of these uses are already approved in some or all states where medicinal marijuana is legal. As can be seen, some of these conditions (e.g., nephropathy, cardiovascular disease, obesity) are more prevalent in people with diabetes, which may make medicinal cannabis use more likely in this population. In fact, at least one study reported on the benefits of CBD for the treatment of diabetic cardiomyopathy, while other research has shown that the endocannabinoid system is intimately involved in the development of many diabetes-associated complications, and highlights that several clinical trials have recently explored targeting cannabinoid receptors for treatment.
Marijuana and Blood Glucose Management
The use of cannabis or its preparations can offer treatment for various health conditions, including ones that are more prevalent in the diabetes population. So, can the compounds affect blood glucose control and what should individuals with diabetes take into consideration to stay safe?
Potential Effects on Blood Glucose Levels
Interestingly, some research has suggested that marijuana users tend to be thinner than non-users and that users may be less likely to develop diabetes. Another study suggested that “chronic cannabis smoking was associated with visceral adiposity and adipose tissue insulin resistance but not with hepatic steatosis, insulin insensitivity, impaired pancreatic β-cell function, or glucose intolerance.”
When it comes to the overall effects of marijuana or its components on blood glucose levels at any specific time of use, no conclusive research is available. Many variables affect blood glucose levels and can include food consumption, medication use, activity, anxiety levels, etc. This means that it’s very important for the individual to self-monitor their blood glucose levels to stay safe.
What to Look Out For
Of course, any person with diabetes should always be on the lookout for hypoglycemia and hyperglycemia and make the appropriate adjustments. Marijuana can affect one’s mental state, so it is important to prepare ahead of time, by setting alarms to check blood glucose levels, or by having another individual with you, who knows about diabetes and can help you check your blood glucose and make the appropriate treatment decisions, if necessary.
Interestingly, a recent study suggested an association between marijuana use and a higher likelihood of developing diabetic ketoacidosis (DKA), a serious and life-threatening complication of diabetes. However, a causal relationship is not clear, the findings are limited by small sample size, and confounding variables, such as income and education level. Patients who used marijuana also happened to have a significantly higher A1c level. It could be that in this case, the cannabis-using population was generally less diligent in their diabetes care for various reasons.
As with using any new medication or recreation drug (such as alcohol), it is imperative that people with diabetes remain in control of their condition by checking their blood glucose levels frequently and adjusting accordingly. If a patient is prescribed medicinal cannabis, it is important to discuss any concerns with a healthcare provider ahead of time and to be extra diligent about checking blood glucose levels frequently during use.
Today, cannabis remains illegal at the federal level, but a gray area is increasingly emerging, for both medicinal and recreational use, as more and more states pass new legislature. We will update this article as more research is conducted, and as state and federal laws are updated.
Akturk HK, Taylor DD, Camsari UM; “Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes” (2018) JAMA Internal Medicine doi:10.1001/jamainternmed.2018.5142 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2712560
Atakan Z; “Cannabis, a complex plant: different compounds and different effects on individuals” (2012) Therapeutic Advances in Pharmacology 2(5): 241-254. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736954/pdf/10.1177_2045125312457586.pdf
Bancks MP, Pletcher MJ, Kertesz SG, Sidney S, Rana JS, Schreiner PJ; “Marijuana use and risk of prediabetes and diabetes by middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study” (2015) Diabetologia 58(12): 2736-2744. https://link.springer.com/article/10.1007/s00125-015-3740-3
Booth M; “Cannabis: A History” (2005) St. Martin’s Press, Picador 1stedition.
Bridgeman MB and Abazia DT; “Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting” (2017) Pharmacy and Therapeutics 42(3): 180-188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312634/
Horvath B, Mukhopadhyay P, Hasko G, Pacher P; “The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications” (2012) The American Journal of Pathology 180(2): 432-442. https://www.sciencedirect.com/science/article/pii/S0002944011010273
Leung L; “Cannabis and Its Derivatives: Review of Medical Use” (2011) Journal of the American Board of Family Medicine 24: 452-462. http://www.jabfm.org/content/24/4/452.full.pdf+html
Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Courville A, Hall G, Chen KY, Volkow ND, Kunos G, Huestis MA, Skarulis MC: “Metabolic Effects of Chronic Cannabis Smoking” (2013) Diabetes Care DC_122303. http://care.diabetesjournals.org/content/early/2013/03/20/dc12-2303.short
National Organization for the Reform of Marijuana Laws (NORML) (2018) http://norml.org
Pacher P and Kunos G; “Modulating the endocannabinoid system in human health and disease—successes and failures” (2013) TheFEBS Journal 280(9): 1918-1943. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684164/
Penner EA, Buettner H, Mittleman MA; “The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults” (2013) The American Journal of Medicine 126(7): 583-589. https://www.sciencedirect.com/science/article/pii/S0002934313002003
Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC; “Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III” (2012) BMJ Open 2: e000494. https://bmjopen.bmj.com/content/2/1/e000494.short
Rajesh M, Muhopadhyay P, Batkai S, et al.; “Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy” (2010) Journal of the American College of Cardiology 56(25) http://www.onlinejacc.org/content/56/25/2115
Whiting PF, Wolff RF, Deshpande S; “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis” (2015)JAMA Network 313(24): 2456-2473. https://jamanetwork.com/journals/jama/fullarticle/2338251?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2015.6358